The Translational Research Core (TRC) is designed to facilitate high quality translational research at the Moffitt Cancer Center. The TRC provides a means to generate pre-clinical data to support investigator initiated trials and resources to quantify the level/activity of molecular targets from clinical specimens obtained from trials. The functionality provided within the Core provides a vital resource for investigators to design and conduct early phase clinical research of novel agents. The Core's overall goals are to provide efficient and proper collection, handling and processing of biological samples, perform sensitive and specific assays and provide the ability to model the data generated. The TRC continues to increase the number of investigators utilizing their services. The Core has also witnessed a greater number of scientific programs requiring services since the last renewal. The capacity of the pharmacologic section has been expanded by the inclusion of a new UHPLC/Tandem Mass Spectrometry system (Thermo Scientific, Accela/TSQ Quantum). Regarding analyses of pharmacodynamic molecular endpoints, the number of active projects continues to grow and is neariy equally divided between clinical and preclinical projects. The Core requests CCSG Support of $125,995, which is 23% of its operational budget.
The Translational Research Core Facility provides researchers with novel approaches and access to the latest technologies with respect to pharmacokinetic drug quantitation and analysis, measurement of pharmacodynamic endpoints, and high-throughput apoptosis assays and combination index analysis for drug interactions. The core is uniquely positioned to provide researchers with a cost-effective, well-managed facility to accomplish their goals.
|Song, Jinming; Hussaini, Mohammad; Zhang, Hailing et al. (2017) Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol 147:444-452|
|Tauro, Marilena; Shay, Gemma; Sansil, Samer S et al. (2017) Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther 16:494-505|
|Davis, Stacy N; Christy, Shannon M; Chavarria, Enmanuel A et al. (2017) A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics. Cancer 123:1390-1400|
|Eksioglu, E A; Chen, X; Heider, K-H et al. (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia 31:2172-2180|
|Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314|
|Heit, Claire; Marshall, Stephanie; Singh, Surrendra et al. (2017) Catalase deletion promotes prediabetic phenotype in mice. Free Radic Biol Med 103:48-56|
|Chen, Yi; Fisher, Kate J; Lloyd, Mark et al. (2017) Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods Mol Biol 1647:19-45|
|Kamath, Vidya P; Torres-Roca, Javier F; Eschrich, Steven A (2017) Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. Int J Genomics 2017:6576840|
|Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449|
|Stewart, Paul A; Fang, Bin; Slebos, Robbert J C et al. (2017) Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. Proteomics 17:|
Showing the most recent 10 out of 1137 publications